Skip to main content
TipRanks
Go Ultimate75% OFF

Exicure (XCUR) AI Stock Analysis

966 Followers
XCUR

Exicure

(NASDAQ:XCUR)

Select Model
Rating:38Underperform
Price Target:$1.00â–¼(-6.54% Downside)
Action:downgraded
Date:11/06/26

The score is driven primarily by severely weak financial performance, including no revenue, ongoing losses, and persistent cash burn. Bearish technical trends, limited valuation support, and ongoing Nasdaq listing risk reinforce the highly speculative profile.

Positive Factors
Debt-Free Balance SheetEliminating total debt reduces leverage and interest-related pressure, giving Exicure a cleaner capital structure than in prior years. This can improve financial flexibility as management evaluates funding, asset monetization, and strategic options, although equity remains limited.
Negative Factors
No Commercial RevenueZero trailing revenue confirms that Exicure has not established a commercial product base and remains dependent on development progress, financing, or transactions. Without recurring sales, operating costs cannot yet be funded internally, limiting visibility into self-sustaining growth.

Exicure (XCUR) vs. SPDR S&P 500 ETF (SPY)

-100%-75%-50%-25%0%25%50%75%XCUR-77.43%SPY+13.31%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$7.00M
Dividend Yield
―
Average Volume (3M)
55.91K
Price to Earnings (P/E)
-0.8
Beta (1Y)
1.75
Revenue Growth
―
EPS Growth
23.05%
Country
US
Employees
1
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Exicure Business Overview & Revenue Model

Company Description

Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combi...

How the Company Makes Money

Exicure did not have a sustained commercial product revenue base; its business model was primarily R&D-driven. The company’s cash inflows historically were mainly from financing activities (e.g., issuing equity and related capital-raising transaction...

Exicure Financial Statement Overview

Summary

Extremely weak financial profile: no TTM revenue, persistent operating and net losses, negative operating and free cash flow, and substantial erosion of equity and assets. Zero debt is a limited strength, but ongoing cash burn and a thin equity base create significant funding risk.

Income Statement

8Very Negative

Balance Sheet

32Negative

Cash Flow

10Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue00500.00K028.83M-483.00K
Gross Profit-263.00K-460.00K500.00K-1.42M26.97M-483.00K
EBITDA-8.55M-5.12M-8.85M-15.54M78.00K-60.63M
Net Income-8.28M-4.95M-9.70M-16.91M-2.58M-64.10M
Balance Sheet
Total Assets11.40M14.04M15.06M11.58M23.33M64.87M
Cash, Cash Equivalents and Short-Term Investments1.72M3.75M12.51M816.00K8.58M39.14M
Total Debt0176.00K5.93M6.67M7.31M14.74M
Total Liabilities10.42M10.12M8.28M8.55M8.41M53.64M
Stockholders Equity977.00K3.93M6.77M3.03M14.92M11.23M
Cash Flow
Free Cash Flow-6.38M-8.56M-2.91M-10.36M-35.67M-35.79M
Operating Cash Flow-6.70M-8.55M-2.91M-10.36M-35.66M-34.82M
Investing Cash Flow563.00K-1.81M0-1.08M4.70M43.09M
Financing Cash Flow01.60M13.40M3.67M-3.10M1.12M

Exicure Technical Analysis

Technical Analysis SentimentNeutral
Last Price1.07

Price Trends

50DMA1.13Negative
100DMA1.36Negative
200DMA2.48Negative

Market Momentum

MACD-0.02Negative
RSI50.76Neutral
STOCH71.12Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XCUR, the sentiment is Neutral. The current price of 1.07 is above the 20-day moving average (MA) of 1.02, below the 50-day MA of 1.13, and below the 200-day MA of 2.48, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 50.76 is Neutral, neither overbought nor oversold. The STOCH value of 71.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for XCUR.

Exicure Risk Analysis

Exicure disclosed 22 risk factors in its most recent earnings report. Exicure reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.It is uncertain if or when we will recognize any royalties or license payments arising from our historical biotechnology intellectual property and other assets.Q3, 2024
2.The restatement of our prior quarterly financial statements may affect stockholder and investor confidence in us or harm our reputation, and may subject us to additional risks and uncertainties, including increased costs and the increased possibility of legal proceedings and regulatory inquiries, sanctions or investigations.Q4, 2023
3.We may not be able to redeem the investment in convertible notes receivable.Q4, 2023

Exicure Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

XCUR against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
UNCYUNCY45Neutral$103.06M-2.31-83.34%――44.11%
XCURXCUR38Underperform$7.00M-0.83-237.91%――23.05%
CRBUCRBU21Underperform$38.12M-0.34-102.74%―1.60%39.34%

* Healthcare Sector Average

Performance Comparison

-50%0%50%XCURUNCYCRBUDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
XCUR and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
XCURExicure1.07-2.66-71.31%
UNCYUnicycive Therapeutics, Inc.3.70-2.22-37.50%
CRBUCaribou Biosciences, Inc.0.35-1.52-81.18%

Exicure Corporate Events

Business Operations and StrategyM&A Transactions

Exicure Agrees to Sell GPC-100 Program Assets

Neutral
Nov 10, 2026

On November 4, 2026, Exicure and its wholly owned subsidiary, GPCR Therapeutics USA Inc., agreed to sell the GPC-100 (burixafor) program assets to Korean company GPCRT Inc. for KRW 6.5 billion, approximately US$4.8 million. The assets included licens...

Delistings and Listing ChangesRegulatory Filings and Compliance

Exicure Receives Nasdaq Extension Amid Ongoing Listing Risk

Negative
Sep 16, 2026

On June 5, 2026, Exicure, Inc. was notified by Nasdaq that it was not in compliance with Listing Rule 5550(b)(1), which requires at least $2.5 million in stockholders’ equity, and that it also failed to meet alternative continued listing standards ba...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 06, 2026